Researcher and professor Dr. Charles Grob discusses The Lundquist Institute’s announcement of a new multi-site clinical trial examining psilocybin for palliative care, the first study of its kind since the 1960’s, in this Q & A with Lucid News.
A newly published review calls for more research into psilocybin’s potential to treat obsessive-compulsive disorder (OCD) based on promising findings and anecdotal reports.
LSD use in American adults rose over 50 percent between 2015 and 2018, a surge that one researcher attributes to rising national chaos.
A network of psychedelic healthcare providers offers a comprehensive global directory of psychedelic clinical trials that are actively enrolling.
A group of Canadian researchers proposes clear guidelines for academic researchers to keep the field of psychedelic science transparent.
Researchers at the University of North Carolina use new techniques to create medicines that duplicate the effectiveness of ketamine and psilocybin as treatments for depression without the psychoactive effects.
The company is researching the anti-inflammatory properties of psychedelics to create new drugs with reduced psychoactivity.
Critical research sponsored by the Eleusis Benefit Corporation could lead to new drugs for Alzeimers and Retinal Disease.
The company is developing a technology that seeks to personalize psychedelic therapy experiences for patients.
In this video interview, Orsini describes how he used LSD to help treat his own autism, and what he’s doing to increase awareness for psychedelic-assisted approaches to treating autism.